30 closest matches · ranked by relevance
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants
Diabetes Mellitus, Type 2 · Insulin Resistance
Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
Diabetes Mellitus, Type 1
Primary: FMD/Shear — 0.182; 0.206; 0.155; 0.219 %/s^-1
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
Aging · Insulin Resistance
Primary: Insulin Sensitivity — -0.16; 2.62; -0.50; 1.83 micro International Units/mL — p=0.023
Cushing Disease
Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
Narcolepsy With Cataplexy
Primary: The Insulin-like Growth Factor 1 (IGF-1) Measured in Fasting Conditions at Baseline (Visit 2) — 207.4 ng/mL
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
Polycystic Ovary Syndrome (PCOS) · Obstructive Sleep Apnea · Obesity
Primary: Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate — 3.13; 2.03; 4.66; 3.36 umol/min/L plasma — p=0.85
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48
Polycystic Ovary Syndrome
Primary: Mean Overnight Growth Hormone Levels — 0.85; 0.84 ng/mL — p=0.918
Anorexia Nervosa
Primary: Areal Bone Density by DXA — 0.88; 0.89 g/cm2
Post-Surgical Hypoparathyroidism
Primary: Percent Change in Fractional Excretion of Calcium (FECa) — -39 percentage of change
Acromegaly · Growth Hormone Deficiency · Pituitary Disease
Primary: Change in High-sensitivity C-reactive Protein — 2.93; 3.23; -0.36; 1.64 mg/liter
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
Obesity
Primary: Peak Growth Hormone (GH) on the GH Stimulation Test — 40.1; 25.2 ng/ml — p=<0.05
Acromegaly · Type 2 Diabetes Mellitus
Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants
Type2 Diabetes
Primary: [11C]5-hydroxy-tryptophan Uptake in the Pancreas — 0.17; 0.21; 0.20; 0.23 % of injected dose — p=0.5875
Insulin Resistance · Diabetes · Obesity
Primary: Body Composition — 39; 39; 37; 39 percentage
Covid19
Primary: Insulin-Like Growth Factor-1 (IGF1) — 142.8; 137.6 ng/ml
Hypothalamic Obesity
Primary: Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². — 1.7; 3.5 percent change from baseline — p=0.40